ReviewTransactions of the American Clinical and Climatological Association2025
REDEFINING AUTOIMMUNE DISEASES: THE OPPORTUNITY FOR PRECISION AND PREVENTION.
Review in Transactions of the American Clinical and Climatological Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From genes to environment: A life-course approach to prevent pediatric autoimmune diseases.World journal of clinical pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
In aggregate, autoimmune diseases affect at least 8% of the U.S. population, making them a significant health problem. Multiple lines of evidence accumulated over the last 20+ years have clearly demonstrated that the pathophysiology leading to autoimmune tissue damage and organ dysfunction occurs over a lengthy and clinically silent time period. As with other chronic diseases, this preclinical phase is an opportunity to identify people at risk and to develop medical and/or lifestyle interventions that can lessen the impact of disease or prevent it entirely. This will require movement away from historical disease definitions that emphasize the clinical features of tissue damage and toward more precise molecular definitions. It is a daunting task that requires large-scale epidemiological studies of immune dysfunction. Ultimately, it creates the opportunity to describe disease "stages" that give patients more clarity about their health and provide researchers, industry, and regulators with a path forward to autoimmune disease prevention.
Indexed as
Identifiers
40771605PMC12323466What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.